Indo Us Bio-Tech Ltd
Indo Us Bio-Tech Ltd (INDOUS) last traded at ₹83.6, a market capitalisation of ₹168 crore, on a P/E of 14.6. Over the past 52 weeks the stock has ranged between ₹75 and ₹159. Indo Us Bio-Tech Ltd last reported results for the quarter ended Jun 2026, with sales of ₹32.99 crore and net profit of ₹3.04 crore. Figures are as of 25 Aug 2026 and are not real time.
Indo Us Bio-Tech Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Indo Us Bio-Tech Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹32.99 cr, up 7.2% from ₹30.77 cr a year earlier. Net profit was ₹3.04 cr, down 35.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 22.17 | 23.56 | 33.38 | 30.77 | 30.85 | 22.8 | 26.02 | 32.99 |
| Expenses | 17.05 | 18.02 | 28.8 | 25.3 | 26.69 | 18.65 | 22.79 | 29.02 |
| Operating profit | 5.12 | 5.54 | 4.58 | 5.47 | 4.16 | 4.15 | 3.23 | 3.97 |
| OPM % | 23.09% | 23.51% | 13.72% | 17.78% | 13.48% | 18.20% | 12.41% | 12.03% |
| Other income | 0.02 | 0.02 | 0.12 | 0 | 0.03 | 0.01 | 0.02 | 0.12 |
| Interest | 0.52 | 0.38 | 0.26 | 0.45 | 0.42 | 0.77 | 0.6 | 0.74 |
| Depreciation | 0.18 | 0.16 | 0.56 | 0.2 | 0.21 | 0.22 | 0.27 | 0.27 |
| Profit before tax | 4.44 | 5.02 | 3.88 | 4.82 | 3.56 | 3.17 | 2.38 | 3.08 |
| Tax % | 2.03% | -0.80% | 4.90% | 2.49% | 3.09% | 5.36% | 17.23% | 1.30% |
| Net profit | 4.36 | 5.05 | 3.68 | 4.7 | 3.45 | 3 | 1.97 | 3.04 |
| EPS (₹) | 2.17 | 2.52 | 1.84 | 2.34 | 1.72 | 1.50 | 0.98 | 1.52 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Indo Us Bio-Tech Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 39 | 49 | 61 | 73 | 104 | 110 | 113 |
| Operating profit | 6 | 7 | 9 | 11 | 19 | 17 | 16 |
| OPM % | 14% | 14% | 15% | 15% | 18% | 15% | 14% |
| Net profit | 5 | 5 | 7 | 8 | 16 | 13 | 11 |
| EPS (₹) | 3.52 | 2.86 | 3.60 | 4.11 | 8.11 | 6.54 | 5.72 |
TTM is the trailing twelve months to the most recent quarter.
Indo Us Bio-Tech Ltd growth and returns
- 10 Years
- 19%
- 5 Years
- 23%
- 3 Years
- 22%
- TTM
- 3%
- 10 Years
- 43%
- 5 Years
- 21%
- 3 Years
- 22%
- TTM
- -36%
- 10 Years
- %
- 5 Years
- 25%
- 3 Years
- -32%
- 1 Year
- -45%
- 10 Years
- 18%
- 5 Years
- 17%
- 3 Years
- 18%
- Last Year
- 15%
Indo Us Bio-Tech Ltd shareholding pattern
Promoters held 68.29% at Jun 2026, down from 70.18% at Jun 2025. FIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.18% | 70.18% | 70.18% | 70.18% | 70.18% | 70.18% | 68.29% | 68.29% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.18% | 0.01% |
| Public | 29.83% | 29.82% | 29.83% | 29.83% | 29.83% | 29.83% | 31.53% | 31.70% |
| No. of shareholders | 971 | 2,828 | 2,780 | 3,112 | 4,130 | 4,738 | 4,531 | 4,690 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Indo Us Bio-Tech Ltd corporate filings
- Submitting Newspaper Advertisement relating to the Unaudited Quarterly Standalone Financial Results for the quarter ended on 30th June, 2026.Company Updatemedium impact
Cruxal's analysis: Indo Us Bio-Tech Limited has released its unaudited standalone financial results for the…
Read the full analysis - Financial Results for the quarter ended on 30-06-2026Resultmedium impact
Cruxal's analysis: Indo US Bio-Tech Limited reported standalone unaudited financial results for the quarter…
Read the full analysis - Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting ....Board Meetingmedium impact
Cruxal's analysis: Indo US Bio-Tech Limited reported standalone revenue from operations of 32.99 crore for…
Read the full analysis - ProceedingsAGM/EGMlow impact
Cruxal's analysis: Indo Us Bio Tech Limited has successfully concluded its postal ballot process, with…
Read the full analysis - Postal Ballot Results by remove e voting process and Scrutinizer''s Report.AGM/EGMlow impact
Cruxal's analysis: Indo Us Bio Tech Limited has successfully concluded its postal ballot process, with…
Read the full analysis - Indo Us Bio-Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve (a) The Unaudited Financial ....Board Meetinglow impact
Cruxal's analysis: Indo Us Bio Tech Limited has announced that its Board of Directors will convene a meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Indo Us Bio-Tech Ltd
Cruxal reads every Indo Us Bio-Tech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.